SCHEMBL3047103

SCHEMBL3047103

NCC1CCCCN1C(=O)c1nc(C2CC2)sc1-c1cccc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 20/20 0.53
HCRTR2 O43614 20/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3043159 0.99 HCRTR1 (0.52) HCRTR1HCRTR2
Hydrochloric Acid SCHEMBL3043151 0.99 HCRTR1 (0.52) HCRTR1HCRTR2
SCHEMBL3053162 0.89 HCRTR1 (0.56) HCRTR1HCRTR2
SCHEMBL3052372 0.88 HCRTR1 (0.51) HCRTR1HCRTR2
Hydrochloric Acid SCHEMBL3050231 0.88 HCRTR1 (0.55) HCRTR1HCRTR2
Hydrochloric Acid SCHEMBL3050228 0.88 HCRTR1 (0.55) HCRTR1HCRTR2
SCHEMBL4786006 0.88 HCRTR1 (0.67) HCRTR1HCRTR2
SCHEMBL3050233 0.86 HCRTR1 (0.46) HCRTR1HCRTR2
SCHEMBL3047100 0.86 HCRTR1 (0.47) HCRTR1HCRTR2
Hydrochloric Acid SCHEMBL3053095 0.86 HCRTR1 (0.45) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155739-B1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-10-06 EP claimed
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 US claimed
EP-2155739-B1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-10-06 EP disclosed
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES HCRTR2, HCRTR1, NPY2R HCRTR1 2/4885HCRTR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.